Organogenesis: Why Is Organogenesis Stock Trading Lower Friday?
Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with read more
Read full article »
President & CEO
Gary S. Gillheeney Sr.
Organogenesis is a Massachusetts-based regenerative medicine company that develops bioactive and acellular biomaterials products to treat orthopedics and spine diseases.
Read more